Zynerba Pharmaceuticals Inc. (ZYNE)

5.57 0 (0%)

IEX Real-Time Price

March 19, 2019 EST.

NASDAQ Global Market : Healthcare

Prev Close 5.57

Price Open 4.94

Volume: 1,467

Avg Volume: 1M

Market Cap: 117.36M

P/E Ratio -2.06

52 Wk Range 2.75-12.5



ZYNE Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-10-15
15.49M
2.57M
4.54
16.60%

2018-09-28
15.5M
2.57M
3.17
16.61%

2018-09-14
15.5M
2M
3.41
12.91%

2018-08-31
15.5M
1.78M
2.59
11.50%




ZYNE Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-11-08
Q3 2018
N/A
-0.69 (1)
-0.47
0.22

2018-08-02
Q2 2018
BTO
-0.77 (3)
-0.89
-0.12

2018-05-08
Q1 2018
N/A
-0.64 (5)
-0.91
-0.27

2018-03-26
Q4 2017
N/A
-0.61 (5)
-0.91
-0.27

News

SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update (2019-03-14 16:39 PR Newswire)

JERSEY CITY, N.J. , March 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, todayreported financial results for the year ended December 31, 2018 , and provideā€¦

 


Statistics

Shares Outstanding: 21.07M

Top 15 Institution Percent: 21.40

Price To Sales: 1217.65

Price To Book: 1.82

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -58.53

Return On Equity: -67.33

Profit Margin: N/A

Price History

Beta: 4.92

50-day Moving Avg: 4.76

200-day Moving Avg: 6.65

YTD Change: 30.11

5-day Change: -5.28

1-month Change: -3.78

3-month Change: 35.20

6-month Change: -38.42

1-year Change: -48.46

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Zynerba Pharmaceuticals Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.zynerba.com

Zynerba Pharmaceuticals Inc together with its subsidiary is a pharmaceutical company which is focused on developing and commercializing proprietary next generation synthetic cannabinoid therapeutics formulated for transdermal delivery.